Though PN-477 is still in the preclinical phase, initial studies from Protagonist Therapeutics and partnered labs have shown extremely promising results in animal models and early pharmacokinetic trials. Here's a breakdown of what we know so far about its performance.
Weight Loss Results
In rodent models of obesity, PN-477 resulted in:
- Up to 30% body weight loss over 12 weeks
- Greater weight reduction compared to semaglutide and tirzepatide
- Enhanced fat oxidation and metabolic rate
Blood Sugar and Insulin
Data from diabetic mouse models show PN-477 led to:
- ~40% decrease in fasting blood glucose
- Improved insulin sensitivity markers
- Reduced HbA1c and triglycerides
Body Composition Improvements
- Fat mass significantly reduced without muscle loss
- Lean mass retention >95%
- Lower visceral fat and improved organ health
Comparison vs Other GLP-1s
Head-to-head in animal testing:
- PN-477 > Tirzepatide for fat loss and glycemic control
- Faster onset of action compared to semaglutide
- More stable weight reduction after stopping therapy
Preliminary Human Data?
While human trials haven’t yet launched, the compound has passed early-stage toxicology testing and stability assessments. Dosing protocols and oral delivery versions are in development.
What’s Next?
- 2025–2026: IND application and Phase 1 human trials
- 2026–2028: Expanded trials for obesity, type 2 diabetes, and NASH
- 2029: Market potential based on trial outcomes
Join the Movement
We’ll be following the official trial results closely. As soon as Phase 1 data is published, you’ll find a full breakdown here — along with interpretation from the PN-477 community.